Followers | 83 |
Posts | 5662 |
Boards Moderated | 1 |
Alias Born | 10/17/2006 |
Friday, April 21, 2017 9:52:41 AM
When people don't listen to Adam Feuerstein they lose money.
He pointed out last Summer, when XBIT was in the mid 20s, that XBIT didn't have a chance.
https://www.thestreet.com/story/13628326/1/xbiotech-cancer-drug-survival-claim-falls-apart-under-scrutiny.html
Recent XBIT News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 05:36:43 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 05:01:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 03:48:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 02:00:25 PM
- XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus • GlobeNewswire Inc. • 01/04/2024 02:00:00 PM
- XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus • GlobeNewswire Inc. • 01/04/2024 02:00:00 PM
- Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis • GlobeNewswire Inc. • 11/14/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 07:41:46 PM
- XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke • GlobeNewswire Inc. • 09/26/2023 01:00:00 PM
- XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer • GlobeNewswire Inc. • 08/30/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 03:18:47 PM
- XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial • GlobeNewswire Inc. • 08/08/2023 03:47:05 PM
- FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients • GlobeNewswire Inc. • 05/22/2023 01:00:00 PM
- XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares • GlobeNewswire Inc. • 05/17/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM